Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last A$92.62 AUD
Change Today -0.13 / -0.14%
Volume 2.0M
As of 2:10 AM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

csl ltd (CSL) Snapshot

Open
A$93.77
Previous Close
A$92.75
Day High
A$93.77
Day Low
A$92.04
52 Week High
08/5/15 - A$102.43
52 Week Low
10/13/14 - A$71.04
Market Cap
43.1B
Average Volume 10 Days
1.7M
EPS TTM
A$2.92
Shares Outstanding
464.8M
EX-Date
09/7/15
P/E TM
22.7x
Dividend
A$1.19
Dividend Yield
1.50%
Current Stock Chart for CSL LTD (CSL)

Related News

No related news articles were found.

csl ltd (CSL) Related Businessweek News

View More BusinessWeek News

csl ltd (CSL) Details

CSL Limited engages in the research, development, manufacture, marketing, and distribution of biopharmaceutical and allied products in Australia, the United States, Germany, Switzerland, and internationally. The company operates through CSL Behring, bioCSL, and CSL Intellectual Property segments. The CSL Behring segment develops, manufactures, and markets plasma products and recombinants, which are used to treat coagulation disorders, including hemophilia and von Willebrand disease, primary immune deficiencies, hereditary angioedema and inherited respiratory disease, and neurological disorders. Its products are also used in cardiac surgery, organ transplantation, and burn treatment, as well as to prevent hemolytic diseases in the newborns. The bioCSL segment manufactures and markets biological products for human use; in-licenses and markets vaccines and prescription pharmaceuticals to treat a range of human medical conditions; and manufactures and markets in vitro diagnostic products. The CSL Intellectual Property segment licenses intellectual property to unrelated third parties. The company also markets a range of vaccines and antivenoms, as well as pharmaceutical products supplied by other manufacturers. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.

Founded in 1916

csl ltd (CSL) Top Compensated Officers

Chief Executive Officer, Managing Director, E...
Total Annual Compensation: $2.9M
Chief Financial Officer
Total Annual Compensation: $1.4M
Chief Scientific officer and Director of R&D
Total Annual Compensation: $1.1M
Executive Vice President of Legal, Group Gene...
Total Annual Compensation: $961.9K
Executive Vice President of Global Commercial...
Total Annual Compensation: $955.6K
Compensation as of Fiscal Year 2015.

csl ltd (CSL) Key Developments

CSL Ltd. Declares Dividend, Payable on October 2, 2015

CSL Ltd. declared a dividend of $0.660 per share. The dividend is payable on October 2, 2015, record date is September 9, 2015 and ex dividend date is September 7, 2015.

CSL Limited Reports Audited Consolidated and Parent Earnings Results for the Year Ended June 30, 2015; Provides Capex Guidance for the Year 2016

CSL Limited reported audited consolidated and parent earnings results for the year ended June 30, 2015. For the year, the company reported sales revenue of USD 5,458.6 million compared to USD 5,334.8 million a year ago. Profit before income tax expense was USD 1,714.0 million compared to USD 1,604.3 million a year ago. Net profit for the period was USD 1,379.0 million compared to USD 1,307.0 million a year ago. Diluted earnings per share were USD 2.914 compared to USD 2.691 a year ago. Net cash inflow from operating activities was USD 1,363.6 million compared to USD 1,360.7 million a year ago. Payments for property, plant and equipment was USD 347.8 million compared to USD 353.9 million a year ago. Payments for intangible assets were USD 66.0 million compared to USD 48.0 million a year ago. For the year, on parent basis, profit for the year was AUD 1,251.9 million compared to AUD 1,055.4 million a year ago. The company anticipates that CapEx will be around USD 500 million for the year 2016.

CSL Ltd. to Report Fiscal Year 2015 Results on Aug 12, 2015

CSL Ltd. announced that they will report fiscal year 2015 results at 8:00 AM, Eastern Daylight on Aug 12, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CSL:AU A$92.62 AUD -0.13

CSL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Astellas Pharma Inc ¥1,804 JPY +23.00
Green Cross Corp/South Korea 201,000 KRW -2,500.00
Grifols SA €36.89 EUR +0.085
Shire PLC 5,025 GBp +10.00
Solvay SA €106.35 EUR +0.45
View Industry Companies
 

Industry Analysis

CSL

Industry Average

Valuation CSL Industry Range
Price/Earnings 22.7x
Price/Sales 5.7x
Price/Book 11.2x
Price/Cash Flow 22.3x
TEV/Sales 5.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CSL LTD, please visit www.csl.com.au. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.